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n the United States, approximately 300,000 patients underwent total hip arthroplasty in 2005, with a projected increase of up to 200% by 2030 1 . Although hospital-associated infections following hip replacement develop in 0.2% to 1.1% of patients 2 , they are serious complications that increase the rate of morbidity and the burden to the health-care system 3 and remain as one of the main reasons for revision arthoplasty 4 . Additionally, patients having a hip replacement are at high risk for venous thromboembolism (VTE) and, without the use of prophylaxis, 15% to 60% of them would develop deep vein thrombosis and 0.5% to 2% would have a fatal pulmonary embolism 5 . In 2008, the U.S. Centers for Medicare and Medicaid Services (CMS) added VTE to the list of preventable complications that are referred to as ''never events,'' thereby reducing the reimbursement amount payable to hospitals if patients experienced these events following hip replacement 6 . Concerns over hospital-associated complications led to the development of clinical guidelines and implementation of process measures such as those from the Surgical Care Improvement Project (SCIP) 7 . There are four SCIP measures against postoperative infections (INF) and two against VTE related to hip arthroplasty. SCIP INF-1 measures the percentage of hospital patients who received prophylactic antibiotics within one hour prior to surgical incision. SCIP INF-2 measures the percentage of hospital patients who received prophylactic antibiotics recommended for their specific surgical procedure. SCIP INF-3 measures the percentage of hospital patients whose prophylactic antibiotics were discontinued within twenty-four hours after surgery end time. SCIP INF-6 measures the percentage of hospital patients with appropriate removal of surgical site hair with clippers or depilatory or those not requiring removal of surgical site hair. SCIP VTE-1 measures the percentage of hospital patients with recommended VTE prophylaxis ordered. SCIP VTE-2 measures the percentage of hospital patients who received appropriate venous thromboembolism prophylaxis (except aspirin) within twenty-four hours before surgery to twenty-four hours after surgery. SCIP measures against infections have been evaluated recently in a multi-institutional setting with minimal reduction in infections identified [8] [9] [10] . Process measures related to VTE prophylaxis are not without controversy. Anticoagulation has been associated with a higher risk of surgical complications, as shown in meta-analysis 11 , casecontrol [12] [13] [14] , retrospective 15 , and prospective 16 cohort studies. These results challenge those of earlier clinical trials in which patients with a higher risk of bleeding and other complications were excluded. Clinicians have long suspected that patients with chemical prophylaxis against VTE have increased wound drainage and hematoma rates, which results in an increased risk of infection 14 . Thus, there remains disagreement regarding the optimal VTE prophylaxis after total hip arthroplasty 17 . One committee 18 has highly recommended pharmacologic prophylaxis, while another committee report 19 has expressed substantial concerns over high rates of bleeding and hematoma among patients with use of prophylaxis.
In this study, we sought to evaluate the effect of the SCIP prevention measures against postoperative infection. Furthermore, we addressed the issue of possible cross-measure association between compliance with SCIP VTE prevention measures and levels of postoperative infections. Because data from the New York State Department of Health were publicly available and the database from AHRQ contained only deidentified information, the study was exempted by the institutional review boards at the National Institutes of Health. Linkage of AHRQ data with other data was performed at the hospital level.
Materials and Methods

Outcome Measures
We obtained a hospital-level rate of surgical site infections following hip replacements from the New York State Department of Health 2008 annual report. Infections were defined as those identified during the patient's initial hospital discharge or readmission, with the clinical definitions as superficial, deep, and organ space infections on the basis of the National Healthcare Safety Network criteria, although the specific types were not listed in the public release file 20 .
Each case of surgical site infection was reported by the individual hospital.
During the pilot year 2007, reports of infection from each hospital were audited for accuracy according to guidelines from the National Healthcare Safety Network 22 .
We also captured the infection outcomes using patient-level data from the state inpatient database. The postoperative infection was ascertained with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. We identified index hospitalizations for hip replacements using ICD-9-CM procedure codes. The postoperative infections were captured either as a secondary diagnosis during initial hospitalization or a readmission with any related diagnosis within the calendar year, into the same hospital or any other HCUP hospitals in the state of New York. We excluded patients with a diagnosis of infection or VTE on admission. The ICD-9-CM codes for postoperative infection were 998.5, 998.51, or 998.59 for those occurring within thirty days after hip replacement and 996.6, 996.60, 996.66, or 996.67 for those occurring within a year after hip replacement.
Data Analysis
We estimated that, on the basis of the assumption that the baseline rate of surgical site infection was 1%, the sample size that was needed to detect a 50% increase in *Based on hospital compliance that was less than the median value of the SCIP VTE-2 measure. †Based on hospital compliance that was higher than the median value of the SCIP VTE-2 measure. ‡All individuals with data on race as missing or those identified as other than white or black. §Data were unavailable for some patients.
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this rate, with 80% power and a 95% confidence level, was 7963 patients for each group. Since we had 17,714 patients in the cohort, we divided the cohort into two groups on the basis of the levels of compliance with SCIP measures. Hospitals with greater than the median level of compliance were designated as the highly compliant group, leaving the others that were equal to or below the median level of compliance as the less compliant group. With surgical volume treated the same way, we analyzed all SCIP measure and surgical volume covariates as binary variables. We used locally weighted polynomial regression or scatterplot smoothing (LOESS) 23 to visualize the nonlinear relationship between the risk-adjusted infection rates and surgical volume or compliance with VTE prevention measures. To further quantify the association between compliance with SCIP measures and infection outcomes, we used generalized linear regression to study such relationships on facility levels and generalized linear mixed models to analyze the patient-level data.
We included the following covariates: age; sex; admission type (emergency, urgent, or elective); comorbidity index (0, 1, 2, or ‡3); hospital surgical volume (twenty to 102, or 103 to 645 total hip replacements [hospitals with a volume of less than twenty total hip arthroplasties per year were excluded, since data from these hospitals were reported as ''not applicable'' in the New York State annual report]); hospital teaching status, location, bed size, and ownership; primary payer; and individual SCIP measures (INF-1, INF-2, INF-3, INF-6, VTE-1, and VTE-2). We incorporated all of the SCIP measures in the final model and eliminated other covariates that were not relevant on the basis of univariate analysis (p > 0.2). The comorbidity index was based on comorbidities identified in hospital discharge records with use of the diagnosis coding of ICD-9-CM 24 . For hospital-level analyses, we used the numbers of infections as outcomes and procedures reported by each hospital as offset to model the infection rates. Because of excessive zero outcomes (forty-five of 128 hospitals), we used the zero-inflated negative binomial regression of the generalized linear model for the hospitallevel data. As for patient-level analysis, we used hierarchical logistic regression from the generalized linear mixed model, taking into consideration patient clustering by hospital. For these two models, we respectively used procedures COUNTREG and GLIMMIX of SAS 9.2 software (SAS Institute, Cary, North Carolina). Statistical tests were performed at a two-tailed significance level of <0.05. 
Source of Funding
Results
Demographic Data
T able I shows the demographic characteristics of 17,714 patients discharged from the 128 hospitals after twentyfive hospitals that performed less than twenty hip arthroplasties per year had been excluded from the total of 153 hospitals (see Materials and Methods). The patient cohort was dichotomized on the basis of the median value of the SCIP VTE-2 prevention measure. Hospitals with higher compliance were more likely to be teaching hospitals, smaller hospitals, and private hospitals in rural areas. *Adherence was based on whether hospital compliance was lower or higher than the median value of respective SCIP measure compliance or case volume. INF-1 indicates that the prophylactic antibiotic was received within one hour prior to surgical incision; INF-2, that prophylactic antibiotics were recommended for the specific surgical procedure; INF-3, that prophylactic antibiotics were discontinued within twenty-four hours after surgery end time; INF-6, that appropriate surgical site hair removal was done or surgical site hair removal was not required; VTE-1, that surgery patients had recommended VTE prophylaxis ordered; and VTE-2, that surgery patients received appropriate VTE prophylaxis within twenty-four hours before surgery to twenty-four hours after surgery. †The values are given as the adjusted OR with the 95% CI in parentheses. ‡Other significant factors were age (p = 0.001) and comorbidity (p = 0.03). §Another significant factor was primary payer (p = 0.002). 1363 There was a significant and negative association between hospital case volumes and risk-adjusted infection rates for the hospitals with £150 hip replacements per year (p < 0.0001) (see Appendix). For hospitals that had >150 hip replacements per year, the association was not significant. In contrast, for hospitals with SCIP VTE-2 compliance higher than approximately 95%, a positive association was found between this compliance and risk-adjusted postoperative infection rates (Fig. 2) . For hospitals with SCIP VTE-2 compliance of £95%, the association was absent. The apparent 54% reduction in postoperative infections seen among high-volume hospitals was mirrored by a 60% increase in infection rates associated with higher adherence to the SCIP VTE-2 measure.
Improvements in Compliance with SCIP Measures
T H E J O U R N A L O F B O N E & JOINT SURGERY d J B J S . O R G VOLUME 94-A d NUMBER 15 d AUGUST 1,
Risk of Postoperative Infections Associated with SCIP VTE Compliance
In the final model for hospital-level analysis that included all of the SCIP measures, hospital case volume, and teaching status, the last two factors were both associated with significantly lower risks of postoperative infections (Table II) . Among all of the SCIP measures, only that with VTE-2 was associated with a significantly higher rate of infections (adjusted odds ratio 
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[OR]: 1.91; 95% CI, 1.31 to 2.79). Similarly, on the patientlevel analysis, the adjusted risks of infection were significantly higher for hospitals with higher compliance with VTE-2 (adjusted OR: 1.50; 95% CI, 1.07 to 2.12; p = 0.02), but not with VTE-1 (p = 0.63).
Subgroup Analysis: Patients with Elective Hip Arthroplasty
Because admission type was a strong confounder for our study (Table II) , we conducted separate analyses for elective and nonelective hip replacements. Table III showed that the risks of postoperative infections were significantly elevated for the patients undergoing elective hip arthroplasty in hospitals that were highly compliant with SCIP VTE-2 measures compared with similar patients from less compliant hospitals (adjusted OR: 2.30; 95% CI, 1.20 to 4.40).
Sensitivity Analysis: Patients with Elective Hip Arthroplasty
Considering the arbitrary nature of setting cutoff at the median value for comparison, we conducted sensitivity analyses to vary the cutoff point for the dichotomization from the default at 50% down to 25% or up to 75%. The results are presented in the Appendix. The cross-measure associations of SCIP VTE-2 compliance with infection outcomes were robust from approximately 42% to about 58% (within 15% of the median [50%]).
Discussion
I mplementation and expansion of the SCIP has greatly improved hospital compliance with its process measures, while mandatory reporting of hospital-associated infections has made the evaluation of these process measures possible. In this report, we linked the publicly available report with hospital discharge records to estimate the impact of hospital compliance with SCIP measures on clinical outcomes of surgical care across a large state in the U.S.
Consistent with recent studies [8] [9] [10] , we did not find any significant effect on postoperative infections due to hospital compliance with SCIP infection prevention measures. Instead, we found an association between hospital compliance with VTE prevention measures and higher levels or risks of postoperative infections. This implies that mandating a complete compliance with SCIP VTE prevention measures may have unintended consequences related to the infection outcomes following hip replacement. To our knowledge, this study is the first to address the potential issue of a cross-measure effect.
Furthermore, we showed that such an association was specific to the VTE-2 measure. For most of the hip replacements, compliance with the VTE-2 measure modality is defined as the timely application of prophylactic agents, including warfarin, low-molecular-weight heparin, or factor Xa inhibitor. Our results are consistent with an etiological relationship between the administration of low-molecular-weight heparin and the ensuing risk related to surgical site infections 16 . A recent meta-analysis study indicated that low-molecular-weight heparin reduced nonfatal VTE at the expense of hematoma formation 25 . Postoperative hematoma formation, wound drainage, and a mean international normalized ratio of >1.5 were risk factors for periprosthetic infection 14 . Therefore, the cross-measure association we observed is not unexpected because of the potential risks of bleeding and other complications following VTE pharmacologic prophylaxis. Additionally, given that the infection rate following hip replacement was low, the absolute increase in the rate of postoperative infections associated with higher compliance with SCIP VTE measures remained small.
Since October 1, 2008, CMS has ceased payment for ''reasonably preventable'' events that included VTE following hip replacement. Around that date, we saw marked increases in hospital compliance with VTE prevention measures. It is likely that these increases were the result of changes in the types of prophylactics and/or timing of prophylaxis that surgeons prescribed for patients. For example, by switching from warfarin to low-molecular-weight heparin, compliance with VTE-2 measures could be more easily implemented and tracked. For surgeons who predominantly prescribed low-molecular-weight heparin, perioperative application may be the determining factor for measure compliance. Both changes have been shown to be associated with increased bleeding episodes 26, 27 , which might lead to more infections.
Our epidemiological investigation provides a unique opportunity to study rare postoperative events such as surgical site infection and VTE. However, there are several important limitations in our study. First, our patient-level data were derived from administrative data, which have questionable sensitivity and specificity, and may introduce biases. Second, both compliance and hospital-reported data were at the facility level, making the association we described ecological in nature. However, the high compliance rates among hospitals mean that most, if not all, patients were compliant, making the ecological fallacy less problematic. Third, although we adjusted for age, sex, insurance status, hospital volume, and comorbidities in our patientlevel analysis, we did not have information about other risk factors such as duration of surgery, American Society of Anesthesiologists (ASA) classification score (a measure of the severity of illness), surgeon volume, posttraumatic osteoarthritis, and preoperative stay 2 . Additionally, we did not single out risk factors such as obesity, diabetes, and coagulation deficiency. However, in our hospital-level analyses, we visualized the cross-measure association by plotting infection rates that had been risk-adjusted by wound class, ASA score, and duration of surgery. Fourth, we did not have data separately for superficial and deep prosthetic infections, which may represent distinctly different clinical outcomes. It should be mentioned that the New York State annual report only summarized the overall proportions of superficial and deep incision infections at 33% and 45%, respectively (with the rest being organ space infections).
Finally, our results from one state may not be generalized to other states or to the U.S. as a whole. Our findings may be specific to the year 2008, a year when the CMS ruling took effect. Overall, in the current state of high compliances for most hospitals, a lack of utility in the SCIP measures with limited crossmeasure effect size is not unexpected and may be inherent within the design of this study. Further studies are needed to replicate these findings and address the utility of SCIP VTE measures for the prevention of their intended outcomes of VTE.
Despite these limitations, our study suggests that hospitals participating in the SCIP might need to consider not only bleeding risk but surgical site infections as well when implementing their VTE prophylaxis guidelines for patients undergoing hip replacement.
In conclusion, for hospitals that provide surgical care for patients undergoing total hip arthroplasty, incremental compliances with SCIP infection prevention measures were not associated with significant reduction in postoperative surgical site infections. Yet, the relationship between VTE prophylaxis compliance and surgical site infections is alarming, given that both VTE and infections are targeted by SCIP performance measures. The nature and clinical importance of this cross-measure association are not known and warrant further investigation.
